ClinicalTrials.gg
RecruitingNCT07619287Updated Sep 28, 2026

An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies

A Phase 1 interventional study of BG-75202 and Hypomethylation Agent (HMA) in Myeloid Malignancy, sponsored by BeOne Medicines. Recruiting at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by BeOne Medicines · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Sep 28, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
118
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.

02

Conditions studied

  • Myeloid Malignancy

Keywords

  • KAT6 inhibitor
03

In context

Lead sponsor

BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), inclusive, at the time of signing the form (ICF).
  • Patients must have a confirmed diagnosis of myeloid based on 2016 World Health Organization criteria, and meet the following categories:

    • ; myeloid malignancies after ≥1 prior systemic therapy, per ELN; 2022 criteria; patients with actionable genetic alteration must have previously received targeted therapies unless , unavailable/inaccessible, or declined by patient.
  • Patients must have a stable (ECOG) Performance Status of 0-2.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to KAT6A/B inhibitors/degraders.
  • A diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia.
  • Known central nervous system involvement by leukemia
  • Use of antileukemic therapies without sufficient

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    Phase 1a: Part A: Dose escalation, BG-75202 monotherapy

    Sequential cohorts of increasing dose levels of BG-75202 will be evaluated as monotherapy.

    Drug: BG-75202

  • Experimental
    Phase 1a: Part B: Dose escalation, BG-75202 + Hypomethylation Agent (HMA)

    Sequential cohorts of increasing dose levels of BG-75202 in combination with Hypomethylation Agent (HMA) will be evaluated.

    Drug: BG-75202 · Drug: Hypomethylation Agent (HMA)

  • Experimental
    Phase 1b: Dose optimization, BG-75202 monotherapy

    Participants will receive BG-75202 monotherapy

    Drug: BG-75202

Interventions

  • DrugBG-75202

    Administered orally

  • DrugHypomethylation Agent (HMA)

    Administered Intravenous (IV) or Subcutaneous (SC)

06

What researchers measure

Primary outcomes

  1. Part 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporarily associated with the use of study treatment, whether considered related to study treatment or not. An SAE is any untoward medical occurrence that, at any dose, * Results in death * Is life-threatening * Requires hospitalization or prolongation of existing hospitalization * Results in disability/incapacity * Is congenital anomaly/birth defect * Is considered a significant medical AE by the investigator based on medical judgement

    Time frame: From first dose to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately18 months

  2. Phase 1a: Recommended Dose for Expansion (RDFE) of BG-75202

    The potential RDFE(s) of BG-75202 as monotherapy or in combination with HMA are based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), with consideration of the tolerability, pharmacokinetics (PK), pharmacodynamics, antitumor activity, and any other available relevant data.

    Time frame: Estimated approximately 18 months

  3. Phase 1b: Dose Optimization: Complete Remission (CR) Rate

    CR rate is defined as the percentage of participants who achieved a best response of CR as assessed by investigator's review.

    Time frame: Up to approximately 12 months

  4. Phase 1b: Dose Optimization: Complete Remission (CR) plus CR With Partial Hematologic Recovery (CRh) Rate

    CR + CRh rate is defined as the percentage of participants who achieved the best response of CR or CRh as assessed by investigator's review.

    Time frame: Up to approximately 12 months

Secondary outcomes

  1. Phase 1b Dose Optimization: Number of Participants with Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporarily associated with the use of study treatment, whether considered related to study treatment or not.

    Time frame: From first dose to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately 18 months

  2. Phase 1b: Time to Response (TTR)

    TTR for CR, CR + CRi, CR + CRh, and ORR, defined as the time from the randomization date, to the first determination of the respective objective response.

    Time frame: Up to approximately 12 months

  3. Phase 1b: CR + Complete Remission with Incomplete Hematologic Recovery (CRi) Rate

    CR + CRi rate is defined as the percentage of patients who achieved a best response of CR or CRi as assessed by investigator's review.

    Time frame: Up to approximately 12 months

  4. Phase 1a: Dose Escalation: CR + CRh Rate

    CR + CRh rate is defined as the percentage of patients who achieved a best response of CR or CRh as assessed by investigator's review.

    Time frame: Up to approximately 12 months

  5. Phase 1a and Phase 1b: Overall response rate (ORR)

    ORR is defined as the percentage of participants who achieved a best response of CR, CRh, CRi, or partial response (PR) as assessed by investigator's review.

    Time frame: Up to approximately 12 months

  6. Phase 1b: Event Free Survival (EFS)

    EFS, defined as the time from the randomization date for Phase 1b, to the date of first documentation of treatment failure per European LeukemiaNet (ELN) 2022 (refractory disease and relapsed disease) or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 18 months

  7. Phase 1b: Overall Survival (OS)

    OS, defined as the time from the randomization date for Phase to the date of death due to any cause.

    Time frame: Up to approximately 18 months

  8. Phase 1b: Transfusion Independence

    Transfusion independence, defined as the proportion of patients who achieve red blood cell and/or platelet transfusion independence according to protocol specified criteria, among patients who are transfusion-dependent at baseline.

    Time frame: Up to approximately 12 months

  9. Phase 1a and Phase 1b: Observed Plasma Maximum Concentration (Cmax) of BG-75202

    Time frame: Up to approximately 5 months

  10. Phase 1a and Phase 1b: Minimum Observed Plasma Concentration (Ctrough) of BG-75202

    Time frame: Up to approximately 5 months

  11. Phase 1a and Phase 1b: Area Under the Plasma Concentration-Time Curve (AUC) of BG-75202

    Time frame: Up to approximately 5 months

  12. Phase 1a and Phase 1b: Terminal Half Life (t1/2) of BG-75202

    Time frame: Up to approximately 5 months

  13. Phase 1b: Recommended Phase 2 Dose (RP2D)

    The RP2D of BG-75202 takes into consideration the totality of data including, but not limited to, PK, pharmacodynamics, safety, tolerability, and antitumor activity.

    Time frame: Up to approximately 18 months

07

Study locations

17 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Sep 2028, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
Jun 1, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Barwon Health the Geelong Hospital · Geelong, Australia
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    1 site added
    Show site
    • Barwon Health the Geelong Hospital · Geelong, Australia

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07619287
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Jun 23, 2026
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Study Director
Contact
clinicaltrials@beonemed.com
877-828-5568
Study Director
study director · BeOne Medicine

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion